Examples of using Clinical programme in English and their translations into Portuguese
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Adverse reactions reported from the clinical programme are those that occurred in the Phase 3 double-blind placebo controlled studies.
Duloxetine Lilly was studied in a clinical programme involving 3,158 patients(1,285 patient-years of exposure)
Adverse reactions reported from the clinical programme in the tabular listing below reflect the rates at which they occurred in the Phase 3,
They returned, in all cases during the clinical programme, to pre-treatment levels, without sequelae, within a few days to
data available with similar compounds, as the use of activated charcoal to reduce absorption of edoxaban has not been specifically studied in the edoxaban clinical programme.
safety of vortioxetine have been studied in a clinical programme that included more than 6,700 patients,
in the voriconazole clinical programme was 18.0%(319/1,768) in adults and 25.8%(73/283)
in the voriconazole clinical programme was 18.0%(319/1,768) in adults and 25.8%(73/283)
In the clinical programme patients aged 1 to<
Stress prevention and control clinical programme(Portugal) Stress management policy in the Belgian federal police force Road access
The Xultophy clinical development programme included approximately 1,900 patients treated with Xultophy.
Approximately 47% of patients experienced adverse reactions in the clinical trial programme.
The adverse drug reactions were determined based on data from the apremilast clinical development programme.
The Brimica Genuair clinical development programme was conducted in patients with moderate or severe COPD.
The Oslif Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD.
The Hirobriz Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD.
The Onbrez Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD.
The safety profile presented in Table 1 is based on the gefitinib clinical development programme and postmarketed experience.
During the clinical development programme the occurrence of cases of melanoma prompted the consideration of a possible association with rasagiline.
In the COPD clinical development programme a total of 6,237 subjects were included in an integrated assessment of adverse reactions.